Biosimilars: US FDA Proposes Streamlined Pathway For Indication Carve-Ins
Executive Summary
Sponsors may submit supplemental applications for additional indications in advance so that approval will coincide with expiration of a reference product’s exclusivity or patent protection, new draft guidance states; agency targets six-month review of such supplements, rather than the 10 months provided under BsUFA II.
You may also be interested in...
New Supplement Timelines, Categories Proposed For BsUFA III
The ideas could potentially address sponsor concerns about the effects of slow reviews.
New Supplement Timelines, Categories Proposed For BsUFA III
The ideas could potentially address sponsor concerns about the effects of slow reviews.
FDA Must Be Quicker On Biosimilar Review
Although the agency committed to six-month reviews of biosimilar and interchangeable supplemental applications, the AAM says that time should, at minimum, be cut in half. Meanwhile, PhRMA's comments on a supplemental applications draft guidance urge the FDA to ensure interchangeability is demonstrated for all indications, even when some of those uses are ineligible for approval due to patent and exclusivity protection.